Huntington National Bank Has $851,000 Stake in Quest Diagnostics Incorporated (NYSE:DGX)

Huntington National Bank decreased its holdings in Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 2.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,981 shares of the medical research company’s stock after selling 203 shares during the period. Huntington National Bank’s holdings in Quest Diagnostics were worth $851,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Quest Diagnostics by 4.8% in the first quarter. Vanguard Group Inc. now owns 14,014,030 shares of the medical research company’s stock valued at $1,917,961,000 after purchasing an additional 636,301 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Quest Diagnostics by 5.6% in the third quarter. Victory Capital Management Inc. now owns 3,414,514 shares of the medical research company’s stock valued at $416,093,000 after purchasing an additional 180,889 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Quest Diagnostics by 3.1% in the second quarter. Geode Capital Management LLC now owns 2,422,912 shares of the medical research company’s stock valued at $339,688,000 after purchasing an additional 72,447 shares during the last quarter. Northern Trust Corp grew its position in shares of Quest Diagnostics by 0.6% in the first quarter. Northern Trust Corp now owns 1,514,577 shares of the medical research company’s stock valued at $207,286,000 after purchasing an additional 8,406 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Quest Diagnostics by 0.3% in the second quarter. JPMorgan Chase & Co. now owns 1,462,970 shares of the medical research company’s stock valued at $205,635,000 after purchasing an additional 4,746 shares during the last quarter. Institutional investors own 87.76% of the company’s stock.

Analysts Set New Price Targets

DGX has been the topic of a number of analyst reports. Citigroup increased their price target on Quest Diagnostics from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday, December 11th. Bank of America raised Quest Diagnostics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $140.00 to $160.00 in a research report on Tuesday, December 12th. Jefferies Financial Group raised Quest Diagnostics from a “hold” rating to a “buy” rating and increased their price target for the stock from $140.00 to $155.00 in a research report on Wednesday. TheStreet downgraded Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday. Finally, Piper Sandler increased their price target on Quest Diagnostics from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Monday, November 6th. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $146.91.

Get Our Latest Analysis on DGX

Quest Diagnostics Stock Up 0.2 %

Shares of DGX opened at $126.74 on Friday. Quest Diagnostics Incorporated has a 52 week low of $119.59 and a 52 week high of $148.91. The stock has a market capitalization of $14.25 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 2.72 and a beta of 0.92. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.20 and a current ratio of 1.31. The stock has a fifty day moving average of $134.49 and a 200-day moving average of $131.70.

Quest Diagnostics (NYSE:DGXGet Free Report) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.04. The company had revenue of $2.29 billion during the quarter, compared to analysts’ expectations of $2.25 billion. Quest Diagnostics had a return on equity of 15.79% and a net margin of 9.23%. Quest Diagnostics’s revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.98 EPS. As a group, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current fiscal year.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 22nd. Investors of record on Monday, April 8th will be given a dividend of $0.75 per share. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.71. This represents a $3.00 annualized dividend and a yield of 2.37%. The ex-dividend date is Friday, April 5th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.92%.

About Quest Diagnostics

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.